Looks like you’re on the UK site. Choose another location to see content specific to your location
Biogen and Ixico expand pilot of Assessa PML platform
Biogen and Ixico have announced plans to expand a pilot of the Assessa PML platform that is currently running in five EU countries.
Assessa PML is a digital companion product to provide neurologists with second opinion reading services if there is a suspicion of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal disease that affects people with multiple sclerosis (MS).
The pilot, which includes platform development and onboarding of participating clinical sites, has now been expanded to include pharmacovigilance reporting, with the effects of medical drugs to be monitored to identify and evaluate previously unreported adverse reactions.
Assessa PML works by facilitating the remote transfer, management and storage of MRI scans to more reliably and effectively offer access to reading expertise for the detection of PML.
The digital platform is based on Ixico's Assessa technology, which has been further developed through a collaboration between Ixico and clinical experts from specialist centres across Europe, with financial support from Biogen.
Giulio Cerroni, chief executive of Ixico, said: "The Assessa PML digital platform is intended to provide technology and speciality services to physicians involved in delivering care to people living with MS."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.
We have hundreds of jobs available across the Healthcare industry, find your perfect one now.
Stay informed
Receive the latest industry news, Tips
and straight to your inbox.
- Share Article
- Share on Twitter
- Share on Facebook
- Share on LinkedIn
- Copy link Copied to clipboard